Department of Urology, Faculty of Medical Science, University of Fukui, Fukui, Japan.
Neurourol Urodyn. 2013 Jan;32(1):70-4. doi: 10.1002/nau.22267. Epub 2012 Jun 12.
The existence of Angiotensin-II (Ang-II) receptors in the bladder wall and the pronounced contractile effect of Ang-II on the human detrusor muscle have been well established. Studies have presented the role of Ang-II as a mediator in smooth muscle growth and collagen production in the bladder with outlet obstruction. We investigated the associations between male lower urinary tract symptoms (LUTS) and hypertension (HT), and examined whether the medications used for HT treatment, particularly Ang-II receptor blockers (ARBs) influence LUTS.
Among 4,298 men with LUTS who were nominated to participate in a Japanese study using the International Prostate Symptom Score (IPSS) to gain information on the effects and the safety of silodosin, a total of 3,790 men for whom a baseline IPSS was available were sub-analyzed. We analyzed the influence of HT treatment on IPSSs.
HT was the most common comorbidity (1,122 men, 29.6%), and 769 men (20.3%) were receiving some kinds of medication for the treatment. We found that the IPSS was lower in patients being treated for HT with ARB than in hypertensive patients who were not receiving any medication (16.8 ± 6.8 vs. 18.3 ± 6.6, P < 0.01). The baseline I-PSS in patients treated for HT with angiotensin converting enzyme inhibitor (ACE-I), calcium channel blocker (CCB), and normotensive patients were 18.3, 19.6, and 18.1, respectively.
The IPSS is lower in patients with HT treated with ARB. Other drugs for HT, including ACE-I and CCB, did not improve the IPSS.
血管紧张素-II（Ang-II）受体存在于膀胱壁中，Ang-II 对人类逼尿肌有显著的收缩作用，这一点已得到充分证实。研究表明，Ang-II 作为一种介质，在伴有出口梗阻的膀胱平滑肌生长和胶原产生中起作用。我们研究了男性下尿路症状（LUTS）与高血压（HT）之间的关系，并探讨了用于 HT 治疗的药物，特别是血管紧张素-II 受体阻滞剂（ARB）是否会影响 LUTS。
在 4298 名因下尿路症状（LUTS）被提名参加日本研究的男性中，使用国际前列腺症状评分（IPSS）来了解西洛多辛的疗效和安全性，其中共有 3790 名男性有基线 IPSS 评分。我们分析了 HT 治疗对 IPSS 的影响。
HT 是最常见的合并症（1122 名男性，29.6%），有 769 名男性（20.3%）正在接受某种药物治疗。我们发现，与未接受任何药物治疗的高血压患者相比，接受 ARB 治疗的 HT 患者的 IPSS 评分较低（16.8±6.8 比 18.3±6.6，P<0.01）。接受血管紧张素转换酶抑制剂（ACE-I）、钙通道阻滞剂（CCB）和血压正常患者治疗的 HT 患者的基线 I-PSS 分别为 18.3、19.6 和 18.1。
接受 ARB 治疗的 HT 患者的 IPSS 评分较低。其他 HT 药物，包括 ACE-I 和 CCB，并没有改善 IPSS。
